QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
QQQ   267.51 (+0.39%)
AAPL   110.08 (+3.03%)
MSFT   202.54 (+1.07%)
FB   248.15 (-1.73%)
GOOGL   1,430.14 (-1.44%)
AMZN   2,960.47 (+0.19%)
NVDA   500.69 (+2.69%)
TSLA   449.39 (+1.64%)
BABA   273.82 (+0.52%)
CGC   15.74 (-3.79%)
GE   6.35 (-7.70%)
MU   49.15 (-3.13%)
AMD   77.94 (+4.02%)
T   28.63 (-1.04%)
F   6.87 (-4.98%)
ACB   6.32 (-3.22%)
GILD   64.21 (-1.29%)
NFLX   487.35 (+3.70%)
DIS   125.41 (-2.50%)
BAC   24.47 (-2.94%)
BA   156.35 (-2.97%)
Log in
NASDAQ:XBIO

Xenetic Biosciences Stock Forecast, Price & News

$0.96
-0.03 (-3.02 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.90
Now: $0.97
$0.99
50-Day Range
$0.83
MA: $1.07
$1.33
52-Week Range
$0.44
Now: $0.97
$1.96
Volume127,326 shs
Average Volume441,342 shs
Market Capitalization$6.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More
Xenetic Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIO
CUSIPN/A
CIKN/A
Phone781-778-7720

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$2.84 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

Employees4
Market Cap$6.08 million
Next Earnings Date11/20/2020 (Estimated)
OptionableNot Optionable
$0.96
-0.03 (-3.02 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

How has Xenetic Biosciences' stock been impacted by COVID-19?

Xenetic Biosciences' stock was trading at $0.7031 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XBIO shares have increased by 37.2% and is now trading at $0.9650.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Xenetic Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xenetic Biosciences
.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Friday, November 20th 2020.
View our earnings forecast for Xenetic Biosciences
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its earnings results on Wednesday, August, 12th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. The business earned $0.11 million during the quarter, compared to analyst estimates of $0.06 million.
View Xenetic Biosciences' earnings history
.

What price target have analysts set for XBIO?

2 equities research analysts have issued 1-year target prices for Xenetic Biosciences' stock. Their forecasts range from $2.00 to $2.50. On average, they expect Xenetic Biosciences' share price to reach $2.25 in the next twelve months. This suggests a possible upside of 133.2% from the stock's current price.
View analysts' price targets for Xenetic Biosciences
.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a increase in short interest in August. As of August 14th, there was short interest totaling 410,800 shares, an increase of 22.3% from the July 30th total of 335,900 shares. Based on an average trading volume of 580,600 shares, the short-interest ratio is presently 0.7 days. Currently, 7.7% of the shares of the company are sold short.
View Xenetic Biosciences' Short Interest
.

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Opko Health (OPK), Biocept (BIOC), Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Vaxart (VXRT), Aytu Bioscience (AYTU), Onconova Therapeutics (ONTX) and Selecta Biosciences (SELB).

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.97.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $6.08 million and generates $20,000.00 in revenue each year. Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.